Sponsored by Eli Lilly and Company in collaboration with TransPharma Medical, a subject and investigator, blind placebo-controlled, dose escalation study of 60 healthy postmenopausal Japanese women was conducted.
“We are very pleased with the results of this study, in which we successfully demonstrated the performance of our new self-applied ViaDerm system as a product intended for home use,” says Dr. Daphna Heffetz, CEO of TransPharma Medical.
“This is an important step toward introducing the ViaDerm system as a household solution for the self-delivery of a variety of medical substances, first and foremost being hPTH(1-34) for the treatment of osteoporosis.”
The debilitating disease affects an estimated 75 million people in Europe, the US and Japan, reducing the density and quality of bone and greatly increasing the risk of fracture.
TransPharma’s ViaDerm drug delivery system incorporates a handheld electronic device, which creates microscopic passageways through the outer layer of the skin allowing for transdermal delivery of a wide variety of drugs from a patch.
TransPharma currently has three drug products in clinical trials.